Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether aliskiren is effective in the treatment of blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease (CKD) patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypertension Chronic Kidney Disease |
Drug: Aliskiren |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Aliskiren on Blood Pressure, Heart and Kidney in Elderly Hypertensive Chronic Kidney Disease Patients |
- The Change of Blood Pressure [ Time Frame: baseline and 6 month ] [ Designated as safety issue: Yes ]The change of systolic blood pressure and diastolic blood pressure
- The Change of Heart Function Confirmed by Echocardiograph [ Time Frame: baseline and 6 month ] [ Designated as safety issue: Yes ]Left ventricular ejection fraction (LVEF)were measured by echocardiogram at baseline and 6 month. Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.
- The Change of BNP [ Time Frame: baseline and 6month ] [ Designated as safety issue: Yes ]Plasma BNP level were measured by the radioimmunoassay (RIA) method at baseline and 6month.
- The Change of eGFR [ Time Frame: baseline and 6 month ] [ Designated as safety issue: Yes ]eGFR was calculated at baseline and at 6 month using a modified version of the Modification of Diet in Renal Disease (MDRD) formula of the Japanese Society of Nephrology as follows: eGFR (ml/min/1.73 m2) = 194 × age-0.287 × serum creatinine-1.094 (multiplied by 0.739 for females).
- The Change of Urine Albumin/ Creatinine Ratio (UACR). [ Time Frame: baseline and 6 months ] [ Designated as safety issue: Yes ]The UACR was measured at baseline, Week12 and Week24
- The Change of Oxidative Stress Markers Confirmed by Plasma Level of 8-OHdG and d-ROM [ Time Frame: 6 months ] [ Designated as safety issue: No ]
| Enrollment: | 23 |
| Study Start Date: | February 2011 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Aliskiren |
Drug: Aliskiren
150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Other Name: Direct renin inhibitor
|
Detailed Description:
Chronic kidney disease (CKD) was reported to be affecting 11% of the all population. This number is much higher in the elderly population and may be as high as 30%. CKD is an independent risk factor of cardiovascular disease (CVD). This is called "Cardio-renal Continuum". The renin-angiotensin-aldosterone system (RAS) plays pivotal roles in both cardiovascular and renal functions.
The increased oxidative stress by activated RAS on vascular endothelium is one of important factor to development of Cardio-renal Continuum. The blockade of RAS by angiotensin I converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) has been reported to ameliorate the renal disease and CVD; however,they do not completely suppress RAS, leading to a reactive rise in plasma renin activity (PRA). Aliskiren, an oral direct renin inhibitor, is effective against essential hypertension by reducing PRA, resulting in more complete suppression of RAS; however, little is known about the effects of aliskiren on heart and kidney functions in elderly hypertensive CKD patients. In this study, we assessed the efficacy of aliskiren on heart and kidney functions in elderly hypertensive CKD patients.
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of Chronic kidney disease
- Clinical diagnosis of Hypertension (Blood pressure >=140/90mmHg)
- Elderly people(>=65 years old)
Exclusion Criteria:
- The patients who are already taking aliskiren
- The patients who are receiving hemodialysis or peritoneal dialysis
- The patients who are taking cyclosporin
- The patients who have hyperkalemia(>=5.5mEq/ml)
- Severe heart failure (>=NYHA class III)
- Insulin dependent diabetic mellitus or poor controlled insulin independent diabetic mellitus (>=HbA1c 9.0&)
- Severe liver dysfunction (five folds increased AST or ALT than standard values)
Contacts and Locations| Japan | |
| Niimi city Yukawa National health insurance clinic | |
| Niimi, Okayama, Japan, 719-2643 | |
| Konan Hospital | |
| Oyama, Tochigi, Japan, 329-0214 | |
| Kurosu Hospital | |
| Sakura, Tochigi, Japan, 329-1395 | |
| Jichi Medical University | |
| Shimotsuke, Tochigi, Japan, 3290498 | |
| Principal Investigator: | Yoshiyuki Morishita, MD, PhD | Division of Nephrology, Department of Medicine, Jichi Medical University |
More Information
Publications:
| Responsible Party: | Yoshiyuki Morishita, MD. PhD, Jichi Medical University |
| ClinicalTrials.gov Identifier: | NCT01284114 History of Changes |
| Other Study ID Numbers: | JMU-N1 |
| Study First Received: | January 25, 2011 |
| Results First Received: | July 5, 2012 |
| Last Updated: | September 19, 2012 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Jichi Medical University:
|
Elderly chronic kidney disease Hypertension Aliskiren |
Additional relevant MeSH terms:
|
Hypertension Kidney Diseases Renal Insufficiency, Chronic Kidney Failure, Chronic |
Vascular Diseases Cardiovascular Diseases Urologic Diseases Renal Insufficiency |
ClinicalTrials.gov processed this record on June 18, 2013